Sagar Rajesh, Pattanayak Raman Deep
Department of Psychiatry, All Institute of Medical Sciences, New Delhi, India.
Indian J Med Res. 2017 Jan;145(1):7-16. doi: 10.4103/ijmr.IJMR_1386_16.
Bipolar disorder (BD) is a severe, recurrent mood disorder, associated with a significant morbidity and mortality, with high rates of suicides and medical comorbidities. There is a high risk of mood disorders among the first-degree relatives of patients with BD. In the current clinical practice, the diagnosis of BD is made by history taking, interview and behavioural observations, thereby lacking an objective, biological validation. This approach may result in underdiagnosis, misdiagnosis and eventually poorer outcomes. Due to the heterogeneity of BD, the possibility of developing a single, specific biomarker is still remote; however, there is a set of promising biomarkers which may serve as predictive, prognostic or treatment markers in the future. The review presents a critical appraisal and update on some of the most promising candidates for biomarkers, namely, neuroimaging markers, peripheral biomarkers and genetic markers, including a brief discussion on cognitive endophenotypes as indicative of genetic risk. The lessons learnt from other fields and specialties in medicine need to be applied to psychiatry to translate the knowledge from 'bench to bedside' by means of clinically useful biomarkers. Overall, the biomarkers may help in pushing the shift towards personalized medicine for psychiatric patients.
双相情感障碍(BD)是一种严重的复发性情绪障碍,与显著的发病率和死亡率相关,自杀率和医学合并症发生率都很高。BD患者的一级亲属患情绪障碍的风险很高。在当前的临床实践中,BD的诊断是通过病史采集、面谈和行为观察来进行的,因此缺乏客观的生物学验证。这种方法可能导致诊断不足、误诊,并最终导致更差的结果。由于BD的异质性,开发单一的特异性生物标志物的可能性仍然很小;然而,有一组有前景的生物标志物,它们可能在未来用作预测、预后或治疗标志物。本文综述对一些最有前景的生物标志物候选物进行了批判性评估和更新,即神经影像学标志物、外周生物标志物和遗传标志物,包括对作为遗传风险指标的认知内表型的简要讨论。从医学的其他领域和专业中学到的经验教训需要应用于精神病学,以便通过临床上有用的生物标志物将知识从“实验室转化为临床应用”。总体而言,这些生物标志物可能有助于推动向精神病患者个性化医疗的转变。